Top

Published in:

Open Access 01-03-2012 | Article

Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database

Authors: P. Blin, R. Lassalle, C. Dureau-Pournin, B. Ambrosino, M. A. Bernard, A. Abouelfath, H. Gin, C. Le Jeunne, A. Pariente, C. Droz, N. Moore

Published in: Diabetologia | Issue 3/2012

Abstract

Aims/hypothesis

Using the Echantillon Généraliste de Bénéficiaires: random 1/97 permanent sample of the French national healthcare insurance system database (EGB), we investigated whether, as previously suspected, the risk of cancer in insulin glargine (A21Gly,B31Arg,B32Arg human insulin) users is higher than in human insulin users. The investigation period was from 1 January 2003 to 30 June 2010.

Methods

We used Cox proportional hazards time-dependent models that were stratified on propensity score quartiles for use of insulin glargine vs human insulin, and adjusted for insulin, biguanide and sulfonylurea possession rates to assess the risk of cancer or death in all or incident exclusive or predominant (≥80% use time) users of insulin glargine compared with equivalent human insulin users.

Results

Only type 2 diabetic patients were studied. Exposure rates varied from 2,273 and 614 patient-years for incident exclusive users of insulin glargine or human insulin, respectively, to 3125 and 2341 patient-years for all patients predominantly using insulin glargine or human insulin, respectively. All-type cancer HRs with insulin glargine vs human insulin ranged from 0.59 (95% CI 0.28, 1.25) in incident exclusive users to 0.58 (95% CI 0.34, 1.01) in all predominant users. Cancer risk increased with exposure to insulin or sulfonylureas in these patients. Adjusted HRs for death or cancer associated with insulin glargine compared with human insulin ranged from 0.58 (95% CI 0.32, 1.06) to 0.56 (95% CI 0.36, 0.87).

Conclusions/interpretation

There was no excess risk of cancer in type 2 diabetic patients on insulin glargine alone compared with those on human insulin alone. The overall risk of death or cancer in patients on insulin glargine was about half that of patients on human insulin, thereby excluding a competitive risk bias.

Yehezkel E, Weinstein D, Simon M, Sarfstein R, Laron Z, Werner H (2010) Long-acting insulin analogues elicit atypical signalling events mediated by the insulin receptor and insulin-like growth factor-I receptor. Diabetologia 53:2667–2675PubMedCrossRef

Shukla A, Grisouard J, Ehemann V, Hermani A, Enzmann H, Mayer D (2009) Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocr Relat Cancer 16:429–441PubMedCrossRef

Rensing KL, Houttuijn Bloemendaal FM, Weijers EM et al (2010) Could recombinant insulin compounds contribute to adenocarcinoma progression by stimulating local angiogenesis? Diabetologia 53:966–970PubMedCrossRef

Le Roith D (2007) Insulin glargine and receptor-mediated signalling: clinical implications in treating type 2 diabetes. Diabetes Metab Res Rev 23:593–599PubMedCrossRef

Kazda C, Slieker L, Ilag L, Byrd R, Rees T, Prince M (2010) Appraising the mitogenicity of insulin analogues relative to human insulin-response to: Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H. Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activity in cultured cancer cells. Diabetes Metab Res Rev 2009; 25(1): 41–9. Diabetes Metab Res Rev 26:145–149PubMedCrossRef

Teng JA, Hou RL, Li DL, Yang RP, Qin J (2011) Glargine promotes proliferation of breast adenocarcinoma cell line MCF-7 via AKT activation. Horm Metab Res 43:519–523PubMedCrossRef

Hemkens LG, Grouven U, Bender R et al (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52:1732–1744PubMedCrossRef

Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G (2009) Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden. Diabetologia 52:1745–1754PubMedCrossRef

Home PD, Lagarenne P (2009) Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 52:2499–2506PubMedCrossRef

10.

Rosenstock J, Fonseca V, McGill JB et al (2009) Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia 52:1971–1973PubMedCrossRef

11.

Colhoun HM, SDRN Epidemiology Group (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52:1755–1765PubMedCrossRef

12.

Suissa S, Azoulay L, Dell'aniello S, Evans M, Vora J, Pollak M (2011) Long-term effects of insulin glargine on the risk of breast cancer. Diabetologia 54:2254–2262PubMedCrossRef

13.

Ljung R, Talback M, Haglund B, Jonasson JM, Gudbjornsdottir S, Steineck G (2011) Insulin glargine use and short-term incidence of malignancies—a three-year population-based observation. Acta Oncol 50:685–693PubMedCrossRef

14.

Simon D, Balkau B (2010) Diabetes mellitus, hyperglycaemia and cancer. Diabetes Metab 36:182–191PubMedCrossRef

15.

Pocock SJ, Smeeth L (2009) Insulin glargine and malignancy: an unwarranted alarm. Lancet 374:511–513PubMedCrossRef

16.

Bowker SL, Yasui Y, Veugelers P, Johnson JA (2010) Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia 53:1631–1637PubMedCrossRef

17.

Gallagher EJ, Fierz Y, Ferguson RD, Leroith D (2010) The pathway from diabetes and obesity to cancer, on the route to targeted therapy. Endocr Pract 16(5):864–873PubMedCrossRef

18.

Call R, Grimsley M, Cadwallader L et al (2010) Insulin–carcinogen or mitogen? Preclinical and clinical evidence from prostate, breast, pancreatic, and colorectal cancer research. Postgrad Med 122:158–165PubMedCrossRef

19.

Zhou XH, Qiao Q, Zethelius B et al (2010) Diabetes, prediabetes and cancer mortality. Diabetologia 53:1867–1876PubMedCrossRef

20.

Johnson JA, Bowker SL (2011) Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia 54:25–31PubMedCrossRef

21.

Simon D (2010) Diabetes treatment with insulin glargine and risk of malignancy: methodological pitfalls and ethical issues. Diabetologia 53:204–205PubMedCrossRef

22.

Giovannucci E, Harlan DM, Archer MC et al (2010) Diabetes and cancer: a consensus report. CA Cancer J Clin 60:207–221PubMedCrossRef

23.

Johnson JA, Pollak M (2010) Insulin, glucose and the increased risk of cancer in patients with type 2 diabetes. Diabetologia 53:2086–2088PubMedCrossRef

24.

Grimaldi-Bensouda L, Marty M, Pollak M et al (2010) The international study of insulin and cancer. Lancet 376:769–770PubMedCrossRef

25.

Martin-Latry K, Begaud B (2010) Pharmacoepidemiological research using French reimbursement databases: yes we can! Pharmacoepidemiol Drug Saf 19:256–265PubMedCrossRef

26.

Monami M, Lamanna C, Balzi D, Marchionni N, Mannucci E (2009) Sulphonylureas and cancer: a case–control study. Acta Diabetol 46:279–284PubMedCrossRef

27.

Monami M, Lamanna C, Pala L et al (2008) Treatment with insulin secretagogues and cancer-related mortality in type 2 diabetic patients a retrospective cohort study. Exp Clin Endocrinol Diabetes 116:184–189PubMedCrossRef

28.

Monami M, Colombi C, Balzi D et al (2011) Metformin and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 34:129–131PubMedCrossRef

29.

Currie CJ, Poole CD, Gale EA (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766–1777PubMedCrossRef

30.

Hernandez-Diaz S, Adami HO (2010) Diabetes therapy and cancer risk: causal effects and other plausible explanations. Diabetologia 53:802–808PubMedCrossRef

31.

Erbel S, Reers C, Eckstein VW et al (2008) Proliferation of colo-357 pancreatic carcinoma cells and survival of patients with pancreatic carcinoma are not altered by insulin glargine. Diabetes Care 31:1105–1111PubMedCrossRef

32.

Schienkiewitz A, Schulze MB, Hoffmann K, Kroke A, Boeing H (2006) Body mass index history and risk of type 2 diabetes: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Am J Clin Nutr 84:427–433PubMed

33.

Kubo A, Corley DA (2006) Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomark Prev 15:872–878CrossRef

34.

Ahn J, Schatzkin A, Lacey JV Jr et al (2007) Adiposity, adult weight change, and postmenopausal breast cancer risk. Arch Intern Med 167:2091–2102PubMedCrossRef

35.

Larsson SC, Wolk A (2007) Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am J Clin Nutr 86:556–565PubMed

36.

Renehan AG, Soerjomataram I, Tyson M et al (2010) Incident cancer burden attributable to excess body mass index in 30 European countries. Int J Cancer 126:692–702PubMedCrossRef

37.

Basen-Engquist K, Chang M (2011) Obesity and cancer risk: recent review and evidence. Curr Oncol Rep 13:71–76PubMedCrossRef

38.

Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29:254–258PubMedCrossRef

39.

Dungan KM, Binkley P, Nagaraja HN, Schuster D, Osei K (2011) The effect of glycaemic control and glycaemic variability on mortality in patients hospitalized with congestive heart failure. Diabetes Metab Res Rev 27:85–93PubMedCrossRef

40.

Mattila TK, de Boer A (2010) Influence of intensive versus conventional glucose control on microvascular and macrovascular complications in type 1 and 2 diabetes mellitus. Drugs 70:2229–2245PubMedCrossRef

41.

Marso SP, Kennedy KF, House JA, McGuire DK (2010) The effect of intensive glucose control on all-cause and cardiovascular mortality, myocardial infarction and stroke in persons with type 2 diabetes mellitus: a systematic review and meta-analysis. Diab Vasc Dis Res 7:119–130PubMedCrossRef

42.

Hill D, Fisher M (2010) The effect of intensive glycaemic control on cardiovascular outcomes. Diabetes Obes Metab 12:641–647PubMedCrossRef

43.

Group AS, Gerstein HC, Miller ME et al (2011) Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 364:818–828CrossRef

44.

Ko KJ, Tomor V, Nathanson BH, Bouchard JR, Aagren M, Dubois RW (2010) Does type of bolus insulin matter in the hospital? Retrospective cohort analysis of outcomes between patients receiving analogue versus human insulin. Clin Ther 32:1954–1966PubMedCrossRef

Title: Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database
Authors: P. Blin
R. Lassalle
C. Dureau-Pournin
B. Ambrosino
M. A. Bernard
A. Abouelfath
H. Gin
C. Le Jeunne
A. Pariente
C. Droz
N. Moore
Publication date: 01-03-2012
Publisher: Springer-Verlag
Published in: Diabetologia / Issue 3/2012
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-011-2429-5

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Please log in to get access to this content

Other articles of this Issue 3/2012

Islet-enriched gene expression and glucose-induced insulin secretion in human and mouse islets

The peroxisome proliferator-activated receptor (PPAR) β/δ agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells

Request for clarification from Ruiter et al regarding ‘Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study’. Reply to Carstensen B [letter]

INS GFP/w human embryonic stem cells facilitate isolation of in vitro derived insulin-producing cells

Fatty acids acutely enhance insulin-induced oxidative stress and cause insulin resistance by increasing mitochondrial reactive oxygen species (ROS) generation and nuclear factor-κB inhibitor (IκB)–nuclear factor-κB (NFκB) activation in rat muscle, in the absence of mitochondrial dysfunction

Muscle microvascular recruitment predicts insulin sensitivity in middle-aged patients with type 1 diabetes mellitus

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page